Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695160 | 0.98 | ALDH1A1 (0.52) | DPP7DRD2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL16695191 | 0.97 | CYP2D6 (0.50) | DPP7DRD2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL7996805 | 0.95 | HRH1 (0.53) | DPP7DRD2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL19043227 | 0.89 | SIGMAR1 (0.58) | ALDH1A1MAPTCYP2D6HPGDSIGMAR1 | |
| SCHEMBL19043651 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP2D6SIGMAR1NPC1 | |
| SCHEMBL20382666 | 0.84 | DRD2 (0.48) | DRD2SLC6A4SLC6A3ALDH1A1LTA4H | |
| SCHEMBL16695377 | 0.81 | DRD2 (0.51) | DRD2SLC6A4SLC6A3LTA4HSIGMAR1 | |
| SCHEMBL11698547 | 0.81 | DPP7 (0.67) | DPP7ALDH1A1TRPV1HPGDSIGMAR1 | |
| SCHEMBL23731939 | 0.81 | SIGMAR1 (0.44) | SLC6A4ALDH1A1CYP2D6SIGMAR1NPC1 | |
| SCHEMBL22638788 | 0.81 | ALDH1A1 (0.54) | DRD2SLC6A4ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118113-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201403-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | Som Innovation Biotech, S.L. (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3865125-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT | Kashiv Biosciences, LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200306225-A1 | STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LTD R&D CENTER (IN) | 2020-10-01 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2481407-A1 | Compounds for use in treating cognitive disorders | Allergan, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2067775-B1 | A N-Acylsphingosine glucosyltransferase inhibitor | GENZYME CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1409467-B1 | A N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITOR | GENZYME CORP (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010039256-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2067775-A1 | Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2009045503-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008011487-A2 | L-BENZYL-L-HYDR0XY-2, 3-DIAMIN0-PROPYL AMINES AND 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONICACID AMIDES FOR CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | DPP7 532/4885DRD2 4753/4885SLC6A4 4370/4885 |
| US-20200306225-A1 | STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF | HPD, CYP1B1, CYP4X1 | DPP7 396/4885DRD2 341/4885SLC6A4 1450/4885 |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | DPP7 532/4885DRD2 4753/4885SLC6A4 4370/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | DPP7 531/4885DRD2 4673/4885SLC6A4 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.